… Atopic dermatitis and skin disease Efficacy and safety of systemic treatments for moderate-to…
In many patients with moderate-to-severe atopic dermatitis (AD), disease activity requires …

Objective. Pimecrolimus cream (SDZ ASM 981), a nonsteroid inhibitor of inflammatory cytokines,
is effective in atopic dermatitis (AD). We assessed whether early treatment of AD signs/…

… Given the lack of head-to-head studies of systemic therapies in moderate-to-severe atopic
dermatitis (AD), network meta-analyses (NMAs) can provide comparative efficacy and safety …

… Together, the results of both trials support the efficacy and safety … Comparisons of efficacy
and safety results between … period, efficacy end point definitions, analysis of efficacy end points…

… This systematic review evaluates the efficacy, safety and economic impact of dupilumab
compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). …

… A prospective, open, multicentre study was performed to investigate the efficacy and safety
of longterm treatment with cyclosporin in adults with severe atopic dermatitis. Subjects were …

… versus placebo in atopic dermatitis.  … atopic dermatitis (AD).1 We do agree with the author
that upadacitanib have revealed a superiority over dupilumab in term of efficacy and safety. Yet…

… Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.  … for evaluating the
efficacy and safety of upadacitinib for the chronic disease of atopic dermatitis. Because of the …

… Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment
options … We sought to assess efficacy and safety of ustekinumab in patients with moderate-to-severe …

… of short-term cyclosporin A treatment in atopic dermatitis patients has been proven, … the
efficacy, safety and the effect of discontinuation of cyclosporin A treatment in atopic dermatitis …